Recombinant monoclonal antibody to ENG. It is a human monoclonal antibody that can be potentially used in the treatment of Hepatocellular Carcinoma, Gestational Trophoblastic Neoplasia, Choriocarcinoma, Placental Site Trophoblastic Tumor, Epithelioid Trophoblastic Tumor, Adult Solid Tumor, Advanced Soft Tissue Sarcoma, Metastatic Breast Cancer, Solid Tumors, Lung Cancer...
This product is a recombinant Human antibody that recognizes CRCP. The antibody was purified by affinity chromatography.
Creative Biolabs delivers an end-to-end CAR-T development pathway—from target/scFv discovery, CAR design and vectoring, and cell engineering to in-vitro/in-vivo efficacy, IND authoring, and manufacturing support. Modular and GMP-aligned, the platform spans autologous and allogeneic routes (incl. TRAC/Cas9 and mRNA) to de-risk translation for hematologic and solid tumor programs.
End‑to‑end TCR‑like antibody services targeting peptide–MHC complexes—covering immunogen design, pMHC screening, affinity maturation, developability optimization, and functional validation—with output as IgG, bispecifics, or CAR constructs to access intracellular‑derived antigens.
Microglia are the resident macrophages in the central nervous system (CNS). One of their most important characteristics is their ability to phagocytose, which plays a pivotal role in maintaining brain homeostasis and responding to neurodegenerative diseases. In vitro microglial phagocytosis assays assist in understanding how microglia maintain tissue homeostasis in healthy and disease states.
This product is a Human antibody that recognizes Human HLA-A*11:01.
This product is a Mouse antibody that recognizes Human Fc P329G LALA.
End‑to‑end solid‑tumor CAR‑T development—from antigen/scFv discovery and CAR optimization to cell engineering, in‑vitro/in‑vivo efficacy, and IND support. Incorporates dual/logic‑gated and armored CARs, plus trafficking and persistence enhancements to overcome the tumor microenvironment and improve safety and translation.
Tailored formulation and conjugation for nucleic acids and biologics, covering LNPs and alternative carriers, ligand-directed strategies (e.g., GalNAc), and full characterization and process development to enhance stability, targeting, and potency with documentation for scale-up and regulatory needs.
Recombinant monoclonal antibody to 4-1BB. This anti-4-1BB antibody is a fully human IgG4 monoclonal antibody targeting the CD137 receptor. It specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells.
This product is a human IgG1, κ antibody that can recognize human NECTIN4.
Recombinant human monoclonal antibody expressed in CHO binds to the human interferon α/β receptor. It is a monoclonal antibody designed for the treatment of systemic lupus erythematosus.
This recombinant monoclonal antibody is a humanized monoclonal antibody that specifically recognizes human IL-23A and has potent affinity against IL-23A. It can also be potentially used in the research of Crohn's disease, psoriasis, psoriatic arthritis, and asthma.
Recombinant Human Antibody (M22) is capable of binding to TSHR, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-TSHR mAb and the CH1-3 region of human IgG and a light chain (LC) encoding VL from anti-TSHR mAb and CL of human kappa light chain. Exists as a disulfide-linked dimer of the HC and LC heterodimer under non-reducing conditions.
Recombinant Human Antibody (FI6V3) is capable of binding to IAV HA, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-IAV HA mAb and the CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-IAV HA mAb and CL of human kappa light chain. Exists as a disulfide-linked dimer of the HC and LC heterodimer under non-reducing conditions.
Primary human astrocytes from Creative Biolabs are isolated from the human brain (cerebral cortex) and can be used to study the function of the CNS and how nerve cells interact.
Recombinant Human Antibody (K1-70) is capable of binding to the TSH receptor (TSHR), expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-TSH receptor (TSHR) mAb and the CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-TSH receptor (TSHR) proteins mAb and CL of human kappa light chain.
This product is a recombinant Human antibody that recognizes PDCD1. The antibody was expressed in mammalian cells with chemically defined culture media and was purified by affinity chromatography.
Custom DNA/RNA oligonucleotide synthesis with broad modification choices (PS, 2′-OMe, 2′-F, LNA, GalNAc, dyes/biotin), multiple scales and purifications, and analytical QC. Includes design consultation and documentation to support research, translational studies, and conjugation-ready formats.
Recombinant Human Antibody (D25) is capable of binding to RSV, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-RSV mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-RSV mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition.
The antibody specifically targets the CD3 epsilon chain present on T lymphocytes. It binds to the CD3 molecule on the surface of T cells. By engaging with CD3, the mAb alters the immune response, offering potential in decelerating the progression of type 1 diabetes.
Integrated ASO development from sequence design and chemistry selection to preclinical PK/PD, safety, delivery (e.g., GalNAc), and CMC—supporting gapmer and steric-blocker approaches to advance programs efficiently toward IND.
Microelectrode arrays (MEAs) are a valuable tool for recording and measuring neuronal activity. This technology allows us to evaluate in real time how neuronal activity behaves in an environmentally controlled environment. In addition to spontaneous neuronal activity, electrical or compound stimulation can be performed, and over 40 different parameters are recorded simultaneously.
This product is a human monoclonal IgG1 kappan antibody targeting the Gnl domain of glycoprotein N (Gn) of severe fever with thrombocytopenia syndrome virus (SFTSV). This antibody shows the ability to neutralize SFTSV broadly, using the antibody neutralization of the SFTSV, which makes the antibody a specific drug and so clinically useful in preventing SFTSV through the treatment studies of diseases caused by infection.
Recombinant monoclonal antibody to Human VEGF is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels. It is licensed to treat various cancers, including colorectal, lung, breast (outside the USA), glioblastoma (USA only), kidney, and ovarian. Bevacizumab is a humanized monoclonal antibody that inhibits angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).
